1,110 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Integrated Quantitative Investments LLC

Integrated Quantitative Investments LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,110 shares of the biotechnology company's stock, valued at approximately $392,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. ExodusPoint Capital Management LP bought a new position in United Therapeutics in the 4th quarter valued at about $1,899,000. World Investment Advisors increased its stake in shares of United Therapeutics by 18.4% during the fourth quarter. World Investment Advisors now owns 1,299 shares of the biotechnology company's stock valued at $458,000 after acquiring an additional 202 shares during the period. Westpac Banking Corp raised its holdings in United Therapeutics by 6.5% during the fourth quarter. Westpac Banking Corp now owns 1,249 shares of the biotechnology company's stock worth $441,000 after purchasing an additional 76 shares in the last quarter. Bryce Point Capital LLC acquired a new stake in United Therapeutics in the fourth quarter worth approximately $1,243,000. Finally, Geode Capital Management LLC increased its position in shares of United Therapeutics by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock valued at $401,184,000 after purchasing an additional 44,277 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $940,373.07. This trade represents a 79.51 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 87,500 shares of company stock worth $30,640,680. 11.90% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on UTHR. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Stock Down 5.7 %

Shares of United Therapeutics stock traded down $16.69 on Thursday, hitting $276.10. 223,867 shares of the company traded hands, compared to its average volume of 451,530. United Therapeutics Co. has a 12-month low of $230.39 and a 12-month high of $417.82. The company has a market cap of $12.40 billion, a PE ratio of 12.11, a PEG ratio of 0.97 and a beta of 0.63. The company has a 50-day moving average price of $326.18 and a 200 day moving average price of $352.23.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the firm earned $4.36 EPS. Equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.